YOLFTbeta
Rxsight Inc

Rxsight Inc

RXST · NASDAQ · Healthcare / Medical Devices

5.32USD-0.06 (-1.12%)

Price History

Full chart

Market Stats

Previous Close5.38
Open5.45
Day Range5.29 – 5.63
52-Week Range4.48 – 13.22
Volume534.55K
Market Cap193.82M
P/E (TTM)0.00
Forward P/E116.28
EPS-1.14
Dividend Yield0.00%
Beta1.16
50-Day Avg6.08
200-Day Avg7.20

About

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Aziz Mottiwala M.B.A.
  • Employees461
  • Headquarters100 Columbia, Aliso Viejo, CA, United States, 92656, USA
  • Websitehttps://rxsight.com

Leadership

  • Dr. Ilya Goldshleger Ph.D.Chief Operating Officer · b. 1975
  • Mr. Eric J. WeinbergChief Business Development Officer · b. 1961
  • Dr. Ronald M. Kurtz M.D.Chief Medical Officer · b. 1963
  • Mr. Aziz Mottiwala M.B.A.President, CEO & Director · b. 1978
  • Mr. Mark WilterdingChief Financial Officer · b. 1978
  • Mr. Oliver MoravcevicVice President of Investor Relations
  • Mr. Jim SchindlerExecutive VP & General Counsel
  • Ms. Maureen O'ConnellExecutive VP of Clinical & Regulatory Affairs
  • Mr. Patrick CullenExecutive VP of Quality & Infrastructure Operations
  • Mr. Adam DasheExecutive Vice President of International

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.24M14.68M22.59M49.01M89.08M139.93M134.48M
Growth (%)-+554.98%+53.92%+116.90%+81.77%+57.09%-3.89%
Cost of Revenue4.06M12.97M18.08M27.68M35.31M40.98M31.47M
Gross Profit-1.82M1.71M4.52M21.33M53.77M98.94M103.01M
Gross Margin-81.17%11.62%19.99%43.52%60.36%70.71%76.60%
Operating Expense44.25M37.11M57.30M84.65M103.85M135.80M151.20M
Operating Income-46.07M-35.41M-52.79M-63.32M-50.09M-36.86M-48.19M
Operating Margin-2055.78%-241.21%-233.64%-129.21%-56.23%-26.34%-35.84%
EBITDA130.20M32.15M-41.01M-57.78M-41.04M-23.76M-38.84M
EBITDA Margin5809.91%219.06%-181.52%-117.90%-46.07%-16.98%-28.88%
Net Income126.22M27.57M-48.69M-66.76M-48.61M-27.45M-38.94M
Net Income Margin5632.31%187.87%-215.50%-136.22%-54.57%-19.62%-28.96%
R&D29.57M21.93M24.50M25.98M29.05M34.37M38.55M
R&D as % of Total Revenue1319.46%149.43%108.44%53.02%32.61%24.56%28.67%
Interest Expense26.00K510.00K3.68M4.95M3.31M21.00K40.00K
Interest Expense % of Total Revenue1.16%3.47%16.30%10.09%3.71%0.02%0.03%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets110.43M100.68M192.72M150.16M182.55M318.56M311.81M
Total Liabilities415.04M398.21M54.48M60.26M22.19M37.33M36.13M
Total Equity-304.61M-297.53M138.24M89.90M160.36M281.24M275.68M
Cash7.96M13.99M24.36M11.83M9.69M16.71M19.95M
Total Debt5.52M30.75M44.93M44.99M3.01M12.30M11.04M
Net Debt-2.44M16.76M20.57M33.16M-6.68M-4.41M-8.91M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-40.62M-35.20M-44.71M-58.85M-41.59M-16.95M-15.51M
Investing Cash Flow-5.87M15.59M-81.91M39.95M-22.13M-99.31M16.89M
Financing Cash Flow1.33M25.24M137.34M6.33M61.52M123.32M1.86M
Capital Expenditure4.09M2.54M1.94M2.39M4.81M5.44M3.83M
Free Cash Flow-44.70M-37.74M-46.65M-61.24M-46.41M-22.39M-19.34M
Dividends Paid---643.00K---
FCF to OCF110.06%107.21%104.34%104.07%111.57%132.10%124.69%
Dividend Paid to FCF----1.05%---

Earnings

Report DateMar 31, 2021Jun 2, 2021Sep 9, 2021Nov 10, 2021Mar 8, 2022May 5, 2022Aug 8, 2022Nov 7, 2022Mar 6, 2023May 9, 2023Aug 7, 2023Nov 9, 2023Feb 28, 2024May 6, 2024Aug 5, 2024Nov 7, 2024Feb 25, 2025May 7, 2025Aug 7, 2025Nov 5, 2025Mar 10, 2026May 6, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate0.000.00-0.70-0.62-0.68-0.60-0.65-0.68-0.75-0.45-0.39-0.35-0.36-0.19-0.11-0.07-0.17-0.08-0.28-0.34-0.34-0.15-0.37-0.42
EPS Actual-1.70-0.36-0.51-0.68-0.58-0.64-0.61-0.61-0.56-0.31-0.28-0.19-0.26-0.12-0.16-0.160.03-0.03-0.29-0.24-0.03-0.19-0.29-
Surprise--27.14%-9.68%14.71%-6.67%6.15%10.29%25.33%31.11%28.21%45.71%27.78%36.84%-45.45%-128.57%117.65%62.50%-3.57%29.41%91.12%-26.67%21.62%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap193.82M
Enterprise Value3.92M
Trailing P/E0.00
Forward P/E116.28
Price / Sales1.52
Price / Book0.77
EPS-1.14
Book Value6.33
Revenue (TTM)127.58M
Gross Profit (TTM)98.88M
EBITDA-51.58M
Profit Margin-36.80%
Operating Margin-40.81%
Return on Equity-17.35%
Return on Assets-10.41%
Shares Outstanding41.59M
Shares Float33.71M
Beta1.16
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 11 analystsTarget 7.57
  • Strong Buy
    4
  • Buy
    2
  • Hold
    3
  • Sell
    2

Ownership Breakdown

Institutions
104.60%
Insiders
6.57%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    3.19M7.66%
  • Millennium Management LLC
    3.03M7.29%
  • No Street GP LP
    2.06M4.94%
  • Nomura Holdings Inc
    2.00M4.81%
  • D. E. Shaw & Co LP
    1.99M4.77%
  • Vanguard Capital Management, LLC
    1.69M4.07%
  • Bank of America Corp
    1.21M2.91%
  • Federated Hermes Inc
    1.20M2.89%
  • Two Sigma Investments LLC
    1.15M2.76%
  • HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
    1.13M2.72%
  • Jacobs Levy Equity Management, Inc.
    1.07M2.56%
  • Acadian Asset Management LLC
    1.02M2.45%
  • Deutsche Bank AG
    962.31K2.31%
  • Geode Capital Management, LLC
    919.89K2.21%
  • State Street Corp
    801.32K1.93%
  • Point72 Asset Management, L.P.
    733.31K1.76%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.23M2.95%
  • BlackRock Advantage Small Cap Core Instl
    1.03M2.48%
  • iShares Russell 2000 ETF
    1.01M2.44%
  • Xtrackers MSCI World Swap ETF 1C
    731.60K1.76%